Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
Background:Pazopanib has activity in relapsed non-adipocytic soft-tissue sarcomas (STS). A series of serum cytokines and angiogenic factors (CAFs) at baseline and changes in soluble vascular endothelial growth factor receptor-2 (sVEGFR2) or placental-derived growth factor (PlGF) levels during treatm...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 July 2012
|
| In: |
British journal of cancer
Year: 2012, Jahrgang: 107, Heft: 4, Pages: 639-645 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/bjc.2012.328 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/bjc.2012.328 Verlag, Volltext: https://www.nature.com/articles/bjc2012328 
|
| Verfasserangaben: | S. Sleijfer, T. Gorlia, C. Lamers, H. Burger, J.-Y. Blay, A. Le Cesne, M. Scurr, F. Collin, L. Pandite, S. Marreaud, P. Hohenberger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 158205665X | ||
| 003 | DE-627 | ||
| 005 | 20220815033233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181018s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/bjc.2012.328 |2 doi | |
| 035 | |a (DE-627)158205665X | ||
| 035 | |a (DE-576)51205665X | ||
| 035 | |a (DE-599)BSZ51205665X | ||
| 035 | |a (OCoLC)1341019941 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sleijfer, Stefan |d 1970- |e VerfasserIn |0 (DE-588)1241051097 |0 (DE-627)1770039406 |4 aut | |
| 245 | 1 | 0 | |a Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma |b an EORTC-STBSG study |c S. Sleijfer, T. Gorlia, C. Lamers, H. Burger, J.-Y. Blay, A. Le Cesne, M. Scurr, F. Collin, L. Pandite, S. Marreaud, P. Hohenberger |
| 264 | 1 | |c 17 July 2012 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.10.2018 | ||
| 520 | |a Background:Pazopanib has activity in relapsed non-adipocytic soft-tissue sarcomas (STS). A series of serum cytokines and angiogenic factors (CAFs) at baseline and changes in soluble vascular endothelial growth factor receptor-2 (sVEGFR2) or placental-derived growth factor (PlGF) levels during treatment were explored for their association with outcome.Methods:Twenty-three baseline CAFs, and sVEGFR2 and PlGF changes were measured in 85 and 32 patients, respectively. Associations between baseline CAF levels and efficacy parameters, plus between-week 12 sVEGFR2 and PlGF levels and pazopanib-specific toxicities were investigated.Results:At baseline, low interleukin (IL)-12 p40 subunit and MPC3 levels were associated with better progression-free survival (PFS) at 12 weeks (PFS12wks), low basic nerve growth factor and hepatocyte growth factor with a better PFS, and low inter-cellular adhesion molecule-1 and IL-2 receptor alpha with prolonged overall survival (OS; all P<0.05). Pazopanib decreased sVEGFR2 and increased PlGF levels. Low sVEGFR2 and high PlGF levels at week 12 were associated with higher-grade hypertension, with TSH elevations and with poorer PFS12wks, and OS (both P<0.05).Conclusion:Several baseline CAFs were related to outcome parameters. Low sVEGFR2 and high PlGF at week 12 associate with several pazopanib-specific toxicities and poorer efficacy. If confirmed, these factors may be used as early markers for response to and toxicity from pazopanib, enabling further individualisation of STS treatment. | ||
| 700 | 1 | |a Hohenberger, Peter |d 1953- |e VerfasserIn |0 (DE-588)1025311469 |0 (DE-627)72202875X |0 (DE-576)370195574 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d Edinburgh : Nature Publ. Group, 1947 |g 107(2012), 4, Seite 639-645 |h Online-Ressource |w (DE-627)320420094 |w (DE-600)2002452-6 |w (DE-576)103746854 |x 1532-1827 |7 nnas |a Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma an EORTC-STBSG study |
| 773 | 1 | 8 | |g volume:107 |g year:2012 |g number:4 |g pages:639-645 |g extent:7 |a Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma an EORTC-STBSG study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/bjc.2012.328 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/bjc2012328 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181018 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1025311469 |a Hohenberger, Peter |m 1025311469:Hohenberger, Peter |d 60000 |d 61800 |e 60000PH1025311469 |e 61800PH1025311469 |k 0/60000/ |k 1/60000/61800/ |p 11 |y j | ||
| 999 | |a KXP-PPN158205665X |e 3029067416 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["158205665X"],"doi":["10.1038/bjc.2012.328"]},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"17 July 2012"}],"relHost":[{"note":["Gesehen am 27.10.25"],"recId":"320420094","language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma an EORTC-STBSG studyBritish journal of cancer","type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1947-","dateIssuedKey":"1947","publisher":"Nature Publ. Group ; Churchill Livingstone","publisherPlace":"Edinburgh ; Edinburgh"}],"part":{"extent":"7","year":"2012","pages":"639-645","volume":"107","issue":"4","text":"107(2012), 4, Seite 639-645"},"id":{"zdb":["2002452-6"],"issn":["1532-1827"],"eki":["320420094"]},"title":[{"subtitle":"BJC","title_sort":"British journal of cancer","title":"British journal of cancer"}],"titleAlt":[{"title":"BJC"}],"pubHistory":["Volume 1, issue 1 (1 March 1947)-"]}],"physDesc":[{"extent":"7 S."}],"language":["eng"],"recId":"158205665X","note":["Gesehen am 18.10.2018"],"person":[{"display":"Sleijfer, Stefan","roleDisplay":"VerfasserIn","role":"aut","given":"Stefan","family":"Sleijfer"},{"given":"Peter","family":"Hohenberger","display":"Hohenberger, Peter","roleDisplay":"VerfasserIn","role":"aut"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"subtitle":"an EORTC-STBSG study","title_sort":"Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma","title":"Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma"}],"name":{"displayForm":["S. Sleijfer, T. Gorlia, C. Lamers, H. Burger, J.-Y. Blay, A. Le Cesne, M. Scurr, F. Collin, L. Pandite, S. Marreaud, P. Hohenberger"]}} | ||
| SRT | |a SLEIJFERSTCYTOKINEAN1720 | ||